Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 76,084 shares of the company's stock, valued at approximately $4,259,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.12% of Rhythm Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. SRS Capital Advisors Inc. grew its position in Rhythm Pharmaceuticals by 740.7% during the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock worth $25,000 after buying an additional 400 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Rhythm Pharmaceuticals during the fourth quarter worth about $37,000. R Squared Ltd purchased a new position in shares of Rhythm Pharmaceuticals during the fourth quarter worth about $44,000. State of Wyoming bought a new position in shares of Rhythm Pharmaceuticals in the fourth quarter worth approximately $61,000. Finally, GF Fund Management CO. LTD. purchased a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $72,000.

Rhythm Pharmaceuticals Trading Up 2.8%

Shares of RYTM stock traded up $1.79 during trading hours on Thursday, reaching $66.18. The company's stock had a trading volume of 690,895 shares, compared to its average volume of 555,586. Rhythm Pharmaceuticals, Inc. has a one year low of $38.85 and a one year high of $68.58. The stock has a market capitalization of $4.21 billion, a P/E ratio of -15.28 and a beta of 2.36. The firm's fifty day simple moving average is $60.44 and its 200 day simple moving average is $57.75.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $37.72 million during the quarter, compared to the consensus estimate of $40.43 million. During the same quarter last year, the firm earned ($2.35) EPS. The business's revenue was up 25.9% on a year-over-year basis. As a group, equities research analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current fiscal year.

Insider Activity at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 7,031 shares of the company's stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $65.09, for a total value of $457,647.79. Following the sale, the insider now owns 19,209 shares in the company, valued at approximately $1,250,313.81. This represents a 26.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Yann Mazabraud sold 75,000 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $51.48, for a total value of $3,861,000.00. Following the transaction, the executive vice president now owns 40,370 shares of the company's stock, valued at $2,078,247.60. The trade was a 65.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 127,630 shares of company stock worth $7,107,346 over the last 90 days. 6.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on RYTM. Morgan Stanley reiterated an "overweight" rating and set a $72.00 price target on shares of Rhythm Pharmaceuticals in a research report on Friday, March 7th. Needham & Company LLC upped their price objective on shares of Rhythm Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research note on Wednesday, May 7th. Canaccord Genuity Group lifted their target price on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Wells Fargo & Company boosted their price target on shares of Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the stock an "overweight" rating in a research note on Monday, April 7th. Finally, Bank of America raised Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price objective on the stock in a research note on Monday, April 7th. Thirteen analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $76.62.

Rhythm Pharmaceuticals Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.